A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Regeneron Pharmaceuticals

Sponsor score: 60

ClinicalTrials ID:NCT06465329

This clinical trial investigates the efficacy and safety of adding a third drug, REGN7075, to cemiplimab and platinum-based chemotherapy in resectable stage II-IIIB NSCLC. Eligible participants must have measurable disease, ECOG PS 0-1, and adequate organ function. The study evaluates side effects, surgical impact, drug levels, and antibody development.

Patient Parameters

Program Overview

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.

The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug.

The study is also looking at several other research questions, including:

  • What are the side effects associated with the investigational treatments in comparison to the control treatment?
  • Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed?
  • How much of the study drug(s) are in the blood at a given time?
  • Does the body make antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)?

Eligibility Criteria

Inclusion Criteria

  1. Histologically confirmed stage II through IIIB (N2) NSCLC, that is considered resectable with curative intent, as described in the protocol
  2. Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1
  3. Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks for submission, as described in the protocol
  4. Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) of 0 to 1
  5. Adequate organ and bone marrow function, as described in the protocol

General Key

Exclusion Criteria

  1. Any systemic anti-cancer therapy or radiotherapy for the current tumor, as described in the protocol
  2. Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, as described in the protocol
  3. Presence of ≥ grade 2 peripheral neuropathy
  4. Another malignancy that is progressing or requires active treatment, as described in the protocol

Arm Specific Exclusion Criteria:

Arm 1:

  1. Grade ≥3 hypercalcemia, as defined in the protocol
  2. Any central nervous system (CNS) pathology that could increase the risk of immune effector cell-associated neurotoxicity syndrome (ICANS), as described in the protocol
  3. Has marked baseline prolongation of the time from the start of the Q wave to the end of the T wave in electrocardiogram(QT)/corrected QT interval (QTc) interval or risk factors for prolonged QTc, as described in the protocol

Note: Other protocol-defined Inclusion/Exclusion criteria apply.

Locations

FACILITYZIPCITYSTATE
Orchard Healthcare Research Inc.60077SkokieIllinois
Detroit Clinical Research Center48334Farmington HillsMichigan
Morristown Medical Center07960MorristownNew Jersey
Providence Portland Medical Center97213PortlandOregon
Lifespan Cancer Institute02903ProvidenceRhode Island
University of Tennessee Medical Center37920KnoxvilleTennessee

Get This Program In Your Inbox

You can sign up and apply your patients for this program.